Eli Lilly and Company (LLY)
| Market Cap | 764.71B |
| Revenue (ttm) | 35.93B |
| Net Income (ttm) | 6.14B |
| Shares Out | 950.41M |
| EPS (ttm) | 6.79 |
| PE Ratio | 118.50 |
| Forward PE | 53.94 |
| Dividend | $5.20 (0.65%) |
| Ex-Dividend Date | Aug 15, 2024 |
| Volume | 3,385,205 |
| Open | 811.87 |
| Previous Close | 821.19 |
| Day's Range | 801.30 - 822.01 |
| 52-Week Range | 446.89 - 966.10 |
| Beta | 0.41 |
| Analysts | Strong Buy |
| Price Target | 871.68 (+8.33%) |
| Earnings Date | Aug 8, 2024 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the... [Read more]
Financial Performance
In 2023, Eli Lilly's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $871.68, which is an increase of 8.33% from the latest price.
News
MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly...
Watch These Eli Lilly Stock Price Levels as Weight-Loss Drug Competition Rises
Eli Lilly (LLY) shares dropped more than 4% on Thursday, continuing a hasty retreat from their record high earlier this month, as investors assessed the possible impact of a promising new weight-loss ...
Is Eli Lilly Stock Headed Toward $1300 Levels?
Eli Lilly stock (NYSE: LLY) has seen its stock rise by around 50% this year, outperforming the broader indices, with the S&P 500 up over 15%. The stock now trades at 63x projected 2024 earnings of $13...
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement
INDIANAPOLIS , July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024. Lilly will also conduct a conference call that d...
Viking's stock pops as obesity-drug contender drags down Eli Lilly, Novo Nordisk
Experimental drug will move to late-stage trials, accelerating development timeline
MORPHIC HOLDING INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Morphic Holding, Inc. - MORF
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Morphic Holding,...
Eli Lilly Gets Green Light to Sell Weight-Loss Drug in China
Eli Lilly and Co. (LLY) announced on its WeChat account Friday that it has won approval from Chinese regulators to sell tirzepatide for weight loss in the country.
Eli Lilly secures weight loss drug approval in China: How do rivals stack up?
Eli Lily's Mounjaro, a weight management drug, has successfully received regulatory approval in China, sending its stock price up during trading today.
Eli Lilly's weight loss drug tirzepatide gets approval in China
Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish rival Novo Nordisk in the ...
Eli Lilly's stock plunges as investors eye obesity-drug competition
Eli Lilly & Co.'s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among obesity-drug developers.
Novo Nordisk, Eli Lilly have strong first-mover advantage: analyst
Emily Field, head of European pharmaceuticals research at Barclays, says it's too early to say what the competitive landscape will look like in five years for the weight loss drug market, as many tria...
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
Shares of weight-loss drug developers including Eli Lilly & Co., Novo Nordisk and Structure Therapeutics fell sharply early Wednesday after Roche Holding AG announced early-stage trial data for its ex...
Novo Nordisk and Eli Lilly shares slide on new obesity drug trial from Roche
Novo Nordisk and Eli Lilly shares slid Wednesday on promising early-stage trial data from Roche's latest obesity drug candidate. Roche said its experimental once-daily pill showed average weight loss ...
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co LLY and maintained a price target of $885.
Pfizer Vs. Eli Lilly Stock – Which Is A Better Pick?
We believe that Eli Lilly stock (NYSE: LLY) is currently a better pick than its industry peer – Pfizer stock , given its better prospects. PFE stock trades at a much lower multiple of 2.8x revenues, v...
Eli Lilly could be next to cross $1 trillion mark, says Jim Cramer
'Mad Money' host Jim Cramer looks at what companies are in the running to join the elite $1 trillion club.
Jim Cramer reviews 8 companies that could top $1 trillion in market cap
CNCB's Jim Cramer on Wednesday reviewed eight stocks that could join the coveted "trillion-dollar stock club," pinpointing Eli Lilly and Tesla as top contenders. Also on the list are Berkshire Hathawa...
Weight Loss Drugs: Challenges with Affordability & Supply
Affordability and supply are key challenges for GLP-1 weight loss drugs but these issues are actively being addressed, notes Maurits Pot. He and Rahul Jasuja assess the market opportunity of this part...
Novo Nordisk Falls as Study Says Eli Lilly Weight-Loss Ingredient More Effective
The stock price of a pair of pharmaceutical companies are moving in opposite directions Tuesday following the publication of a new scientific study, with Eli Lilly (LLY) shares rising and American dep...
Mounjaro patients lose weight faster than those on Ozempic: Study
Shares of Novo Nordisk (NVO) are falling after a new study found that Eli Lilly's (LLY) GLP-1 weight-loss drug tirzepatide (Mounjaro) leads to faster and greater weight loss results than semaglutide (...
Novo Nordisk's stock slumps after study finds Wegovy lags Lilly's Mounjaro in speed and scale of weight loss
The stock of Danish biotech Novo Nordisk was down 1.6% premarket Tuesday, after a study found that the company's obesity drug Wegovy lags its main rival, Eli Lilly & Co. Inc.'s Mounjaro, in speed and ...
Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss
Shares in Novo Nordisk , maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to fa...
Biggest indicators for weight loss drugs are yet to come, says Jim Cramer
'Mad Money' host Jim Cramer talks today's massive tech run into a record close and how non-tech players are pushing toward the top.
PARA/Skydance Agreement, LLY to Acquire MORF, NOW Downgrade
Paramount (PARA) enters a definitive merger agreement with Skydance Media. Eli Lilly (LLY) is acquiring Morphic Therapeutics (MORF) for $3.2B cash.
Eli Lilly to acquire Morphic in $3.2B deal
Pharmaceutical giant Eli Lilly (LLY) has reached an agreement to purchase biopharmaceutical company Morphic (MORF) in a deal valued at $3.2 billion. This strategic move marks a notable expansion in El...